Review | Open Access | Volume 9 (4): Article  196 | Published: 18 Nov 2026

Epidemic meningococcal meningitis in West Africa: Historical lessons for vaccination policy and future prevention

Ibrahim Adamu1,2,&, Umar Yahya Adamu1,2, Dayyibatu Sani Jauro1, Idris Mohammed1,2

1Department of Medicine, Federal Teaching Hospital Gombe, Gombe State, Nigeria, 2Department of Medicine, Gombe State University, Gombe State, Nigeria

&Corresponding author: Ibrahim Adamu, Department of Medicine, Gombe State University, Gombe State, Nigeria, Email: ibbomala@gsu.edu.ng

Received: 18 May 2025, Accepted: 16 Nov 2026, Published: 18 Nov 2026

Domain: Infectious Disease Epidemiology

Keywords: Epidemic Meningococcal meningitis, African Meningitis belt, West Africa, MenAfriVac, Men5CV

©Ibrahim Adamu et al. Journal of Interventional Epidemiology and Public Health (ISSN: 2664-2824). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Ibrahim Adamu et al., Against the clock: Effect of late detection of a mumps outbreak in the Western North Region of Ghana, 2022. Journal of Interventional Epidemiology and Public Health. 2026; 9(4):196. https://doi.org/10.37432/jieph-d-26-00158

Abstract

Introduction: Epidemic meningococcal meningitis has caused recurrent epidemics, substantial mortality, and health-system disruption across the African meningitis belt for more than a century. Despite advances in vaccine development, evolving serogroup distribution and the challenges of sustaining preventive vaccination continue to shape epidemic risk. Revisiting historical experience is therefore important for informing current vaccination policy and future prevention strategies. This narrative review examines the historical evolution of meningococcal meningitis control in West Africa, focusing on the translation of epidemiological evidence into vaccination policy and the implications for future epidemic prevention.
Methods: Historical and epidemiological literature, policy documents, and programme reports were identified through targeted searches of PubMed, Google Scholar, and World Health Organization (WHO) archives. Sources were selected for their relevance to major epidemics, vaccine development and deployment, and policy decisions. The review adopts an interpretive approach rather than a systematic or scoping review methodology; no formal protocol was registered.
Results: The Bauchi mass vaccination campaign of 1978–1980 provided early observational evidence of the feasibility of large-scale polysaccharide vaccination and documented a subsequent decline in reported meningococcal disease. However, limitations of first-generation vaccines, resource constraints, and uncertainty surrounding preventive strategies prevented wider implementation. The 1996 epidemic further demonstrated the substantial burden of disease and the limitations of predominantly reactive outbreak control. The introduction of MenAfriVac subsequently contributed to a substantial reduction in serogroup A disease in vaccinated populations. However, the emergence of non-A serogroups and the introduction of the pentavalent meningococcal conjugate vaccine (Men5CV) underscore the need for broader, sustained prevention strategies.
Conclusion: Historical experience suggests that vaccine availability alone is insufficient to ensure sustained epidemic prevention. Progress towards the WHO 2030 meningitis-control target requires context-appropriate vaccination strategies, equitable coverage, sustained financing, reliable vaccine supply, effective surveillance, and strengthened regional preparedness. The central argument is that translating vaccine advances into durable population-level protection depends on aligning scientific progress with sustainable implementation and health-system capacity.

Introduction

Neisseria meningitidis is a Gram-negative bacterium that can cause rapidly progressing meningitis and septicaemia with high case-fatality rates and significant risk of severe neurological sequelae in survivors [1]. While it is a global pathogen, its most profound impact is felt in the “African Meningitis Belt,” a region of sub-Saharan Africa stretching from Senegal in the west to Ethiopia in the east, where large-scale epidemics occur with predictable seasonality [2]. This review focuses on the West African portion of this belt encompassing countries that include Nigeria, Niger, Burkina Faso, Mali, and Ghana. This review examines the historical evolution of meningococcal epidemics and vaccination policy in West Africa.

The propensity for epidemics in this region is driven by a confluence of factors: the dry, dusty Harmattan wind, which damages the pharyngeal mucosa and facilitates carriage and bacterial invasion; high atmospheric temperature; low absolute or relative humidity; overcrowding; and the low population immunity against prevalent serogroups due to lack of vaccination [3]. Poor nutrition, poverty, and poor environmental conditions are further compounding factors. For decades, these epidemics were dominated by N. meningitidis serogroup A (NmA) that causes hundreds of thousands of cases and tens of thousands of deaths during peak epidemic years [4].

Sporadic cases of meningococcal meningitis (cerebrospinal meningitis, CSM) blend with other infections prevalent in sub-Saharan Africa, so do not require special attention. Epidemics of the disease are however a serious public health problem because they upset almost the entire healthcare effort, as most attention is diverted towards controlling them. Epidemics are deadly, disruptive and emotionally overwhelming among the affected community. Following the failure of chemotherapy to prevent or curtail epidemics of the disease as a result of the causative organism becoming increasingly resistant to the agents used – sulphonamides and penicillins – it became imperative to look for other means of prevention and control. Vaccination was the obvious alternative, so vaccines were developed against the capsular polysaccharides (PS) of the meningococcus.

The collapse of chemoprophylaxis created an urgent need for a new strategy, which was met by the development of polysaccharide (PS) A+C vaccines, which led to the control of serogroup A, the main serogroup responsible for epidemics in Africa. While later critique would rightly note their limitations being T-cell independent and offering shorter duration of protection, especially in infants, their initial deployment in the field yielded dramatic successes in epidemic control.

This review is timely for three reasons. First, the WHO has set a target of eliminating epidemic meningococcal meningitis as a public health problem by 2030, and the introduction of the pentavalent conjugate vaccine (Men5CV) represents an important tool for advancing that goal. Second, the post-MenAfriVac emergence of non-A serogroups (C, W, X and Y) has created a changing epidemiological landscape that requires an adaptive policy response. Third, historical experience provides an opportunity to examine how epidemiological evidence, vaccine availability, surveillance and implementation constraints have shaped prevention strategies. Understanding why earlier opportunities were not consistently translated into sustained preventive action is therefore directly relevant to current policy decisions.

The objectives of this narrative review are to trace the historical evolution and epidemiology of meningococcal meningitis epidemics in West Africa from the early 20th century to the present; examine the evolution of meningococcal vaccination policy, with particular emphasis on historical policy gaps, missed opportunities and implementation challenges in the transition from reactive to preventive vaccination; and evaluate the contributions of the Bauchi mass vaccination campaign (1978–1980), the 1996 epidemic and the introduction of MenAfriVac to the development of meningococcal disease prevention strategies.

Methods

Review design and scope
This article is a narrative review of the historical evolution of meningococcal meningitis epidemic, prevention and vaccination policy in West Africa. It examines the development of reactive and preventive vaccination strategies, the Bauchi mass vaccination campaign of 1978–1980, the 1996 meningitis epidemic, the introduction and impact of MenAfriVac, and the implications of Men5CV for future disease prevention. The review draws on historical, epidemiological, programmatic and policy literature to interpret developments in meningococcal disease control and identify lessons for contemporary vaccination policy.

Information sources and search strategy
Relevant literature was identified through targeted searches of PubMed, Google Scholar and World Health Organization (WHO) publications and archives. The searches focused on meningococcal meningitis in West Africa and the African meningitis belt, historical epidemics, meningococcal polysaccharide and conjugate vaccines, reactive vaccination strategies, the Bauchi vaccination campaign, the 1996 epidemic, MenAfriVac, Men5CV and the WHO global roadmap for meningitis control. Search terms and combinations included “meningococcal meningitis,” “epidemic meningitis,” “West Africa,” “African meningitis belt,” “epidemics,” “reactive vaccination,” “preventive vaccination,” “meningococcal polysaccharide vaccine,” “meningococcal conjugate vaccine,” “Bauchi vaccination campaign,” “1996 meningitis epidemic,” “MenAfriVac,” “Men5CV,” “meningitis prevention policy,” and “WHO meningitis roadmap 2030, with additional sources identified through the reference lists of relevant publications and historical or policy documents. No formal review protocol was registered.

Source selection and synthesis
Sources were selected for their relevance to the review objectives, historical significance, epidemiological contribution or relevance to vaccination policy. The review considered peer-reviewed research, outbreak reports, historical accounts, WHO guidance and other relevant programme and policy documents. Particular attention was given to sources reporting epidemic burden, vaccination strategies, vaccine effectiveness or impact, implementation challenges and changes in prevention policy. The evidence was synthesised narratively and organised chronologically and thematically to examine the relationship between historical epidemic experience, vaccine development and evolving prevention strategies.

Ethical consideration
This study is a review of publicly available published literature and did not involve the collection of primary data from human participants. Therefore, ethical approval and informed consent were not required. No administrative permissions were required to access the literature reviewed, as all sources are publicly available.

Results

Historical origin and introduction of meningococcal epidemics into West Africa
Meningococcal meningitis was first documented in Geneva in 1805, with subsequent reports in North Africa, including an epidemic among French soldiers in Algiers in 1840 [1,2]. By the late nineteenth century, epidemics had also been recorded in Egypt and Sudan, including a major outbreak in Omdurman in 1898 [5]. Although the precise origin of the epidemic strain responsible for the early West African outbreaks remains uncertain, historical accounts suggest that it may have reached the region from Sudan [5,6]. Possible routes of introduction included the movement of West African pilgrims travelling overland through present-day Chad and Sudan to and from the Arabian Peninsula, as well as the return of West Africans who had served in the Mahdist armies. These movements followed established trans-Saharan and caravan routes and may have facilitated the spread of the organism into West Africa. This account remains a historical hypothesis rather than definitive evidence of a single route or source of introduction [5,6].

Historical overview of meningococcal meningitis epidemics in West Africa
The West African region, situated at the core of the “African meningitis belt,” has been the global epicentre of meningococcal meningitis outbreaks for more than a century. Its history reflects a persistent and evolving public health challenge. Since the first recorded outbreak of meningococcal meningitis in Geneva in 1805 [1], numerous epidemics have occurred worldwide, with the belt stretching from Senegal to Ethiopia consistently experiencing the highest burden [7]. Below, we summarise the major outbreaks documented in the West African segment of the belt by country and period.

The first major epidemic in West Africa was recorded in 1905, when 32 cases of epidemic meningitis were reported in Zungeru, northern Nigeria [3] and later in Yola several miles from Zungeru [8], with subsequent spread to most of northern Nigeria. The extent of this epidemic was uncertain, however; it is estimated that there were at least 20,000 cases and many thousands of deaths [5]. The epidemic spread rapidly westwards and by 1906, it reached northern Ghana [9]. Further epidemics occurred in Ghana in 1919, which also affected Nigeria and Niger. Additional epidemics occurred in Burkina Faso (then Upper Volta) and Ghana in 1939, Mali in 1940, and Dakar in 1941 [10]. In 1979, Nigeria experienced its third consecutive year of epidemic serogroup A meningococcal meningitis.

The most significant wave of epidemics occurred between 1995 and 1997, during which more than 250,000 cases were reported across the region. The epidemic of meningococcal A ST-5 of the clone complex 5 (cc5) began in 1995 in Niger, with 26,738 cases [10]. It peaked in 1996 when over 150,000 cases were reported: 42,129 in Burkina Faso, 7,244 in Mali, 16,050 in Niger, and 75,069 in Nigeria [11]. Transmission continued into 1997, with Burkina Faso reporting 21,504 cases and Mali 10,960 cases. Subsequent spread was recorded in Ghana (18,551 cases), Togo (2,845 cases), and The Gambia (913 cases), while Niger experienced a decline to 3,922 cases [10]. The cc5 clone remained responsible for subsequent epidemics across the belt.

Although serogroup A (Neisseria meningitidis A) had historically been the predominant cause of epidemics worldwide and within the belt, the introduction of the meningococcal A conjugate vaccine MenAfriVac in 2010 marked a major turning point. Following mass vaccination campaigns of MenAfrVac, cases of NmA declined dramatically, and NmA epidemics were effectively eliminated, with confirmed NmA cases reduced by over 99% in vaccinated areas [12-14].

However, the post-MenAfriVac era has seen the rise of non-A serogroups, particularly serogroup C [14,15]. Between December 2016 and June 2017, northern Nigeria experienced the largest global epidemic of serogroup C meningococcal meningitis, with 14,518 suspected cases and 1,166 deaths [15]. Of the 1,339 samples tested, 433 (32%) were positive for bacterial pathogens, including 358 (82.7%) confirmed cases of NmC. Similarly, between January and June 2015, Niger reported 9,367 suspected cases and 549 deaths, with 1,147 (71.5%) laboratory-confirmed NmC cases [16].

Other serogroups have also emerged. NmW135, first noted in 2000, caused a substantial outbreak in Burkina Faso in 2002, introduced largely by returning pilgrims from Saudi Arabia [17]. Serogroup X (NmX) outbreaks have occurred in multiple countries, including Niger (2006), Togo (2008), Ghana (2009), Burkina Faso (2010), and Mali (2014) [10].

West Africa has carried a heavy meningitis burden for more than a century. While MenAfriVac represents a landmark achievement in eliminating serogroup A epidemics, the emergence of serogroups C, W, X, and others underscores the ongoing need for strengthened surveillance and the development of broad, multivalent conjugate vaccines to sustainably control meningococcal disease in the region.

The rise and limitations of reactive control
The introduction of sulphonamides for the treatment of meningococcal meningitis represented an important development in the clinical management of the disease. Early reports described substantial reductions in mortality following treatment, with cure rates reported to be approximately 90% over the initial years of their use. These drugs, popularly known as M&B tablets after their manufacturer, May & Baker, were widely used in clinical practice. However, their tablet formulation presented practical challenges in patients with severe disease, particularly those with impaired consciousness who could not swallow. In settings where injectable formulations were unavailable, crushed tablets were sometimes administered through a nasogastric tube.

The use of sulphonamides also extended beyond individual case management to community-level interventions during epidemics. Building on earlier observations in Oxford, Vollum and Griffiths reported the administration of sulphadimidine snuff to approximately 99% of a population estimated at 100,000 during the 1960–1961 meningitis epidemic in Katsina, northern Nigeria. They described a substantial reduction in disease incidence among the treated population compared with an adjacent untreated community [18]. Although this experience suggested a potential role for mass chemoprophylaxis in epidemic control, its interpretation must consider the limitations of the observational comparison, including the possibility of differences between the populations and their exposure to infection.

Chemotherapy nevertheless had important limitations as a public health strategy. Although effective antimicrobial treatment could reduce morbidity and mortality, it did not provide durable population-level immunity or reliably prevent subsequent epidemics. Moreover, increasing antimicrobial resistance among meningococci reduced the effectiveness of sulphonamides and other antibiotics, including penicillins, in particular settings [19,20]. These limitations, alongside the recurrent nature of epidemics in the African meningitis belt, strengthened the rationale for vaccination as a complementary preventive strategy.

Reactive vaccination was particularly relevant when an outbreak was detected in a defined population at increased risk, provided that an appropriate vaccine was available and could be deployed in time to influence transmission. Its potential advantages included targeted use of limited vaccine supplies, rapid protection of susceptible populations, and the possibility of interrupting or limiting an outbreak. However, its effectiveness depended on timely detection, confirmation of the causative serogroup, vaccine availability, campaign implementation, and the time required for protective immunity to develop. Reactive vaccination could therefore be less effective when surveillance was delayed, transmission had already become widespread, or the available vaccine did not adequately cover the circulating strain.

The transition from reliance on chemotherapy towards vaccination was consequently not simply a response to antimicrobial resistance. It reflected the recognition that treatment and chemoprophylaxis alone could not provide sustained protection against recurrent meningococcal epidemics. Reactive vaccination offered an important outbreak-control option under appropriate epidemiological and operational conditions, while preventive vaccination provided an opportunity to reduce population susceptibility before epidemics occurred. The relative roles of these approaches depended on the epidemiology of disease, vaccine characteristics, surveillance capacity, and the feasibility of timely intervention.

Early vaccine development and the immunological basis of protection
When chemoprophylaxis proved insufficient to prevent recurrent epidemics of cerebrospinal meningitis (CSM), vaccination emerged as an important strategy for reducing the burden of meningococcal disease. Foundational studies by Goldschneider, Gotschlich and Artenstein at the Walter Reed Army Institute of Research demonstrated an association between susceptibility to systemic meningococcal disease and low concentrations of serum bactericidal antibodies against Neisseria meningitidis [21]. These findings established the importance of antibody-mediated protection and informed the development and evaluation of meningococcal vaccines.

Early meningococcal vaccines consisted primarily of purified capsular polysaccharides, which stimulate the production of serogroup-specific antibodies. A systematic review of serogroup A polysaccharide vaccine trials, for example, estimated efficacy at 95% (95% confidence interval [CI]: 87–99%) during the first year after vaccination, although protection beyond this period was less precisely established [22]. These vaccines subsequently became useful tools for controlling meningococcal epidemics. However, their performance varied by serogroup, age and time since vaccination, limiting their suitability for sustained protection through routine childhood immunisation.

A major limitation of plain polysaccharide vaccines was their immunological mechanism. Because capsular polysaccharides act predominantly as T-cell-independent antigens, they induce antibody responses without the robust T-cell help required for effective germinal-centre responses and the development of long-lived immunological memory [23]. Consequently, antibody concentrations may decline over time, and repeat vaccination does not reliably produce the booster responses typically observed with protein-conjugate vaccines. Protection is particularly limited in young children: responses to some meningococcal polysaccharide antigens are weak in children younger than two years, making these vaccines unsuitable for reliable protection in this age group [24]. Furthermore, polysaccharide vaccines do not substantially reduce nasopharyngeal carriage, limiting their capacity to interrupt transmission and generate indirect protection among unvaccinated individuals [25].

The development of protein-conjugate vaccines addressed several of these limitations. By covalently linking capsular polysaccharides to carrier proteins, conjugate vaccines facilitate antigen processing and T-cell-dependent B-cell responses. This mechanism promotes affinity maturation, immunological memory and more sustained antibody responses. Conjugate vaccines can therefore protect in infancy and early childhood, although the magnitude and duration of protection depend on the vaccine formulation, age at vaccination, immunisation schedule and circulating serogroup [25]. Their ability to reduce carriage of vaccine-covered meningococcal strains also creates the potential for indirect protection through reduced transmission. This population-level effect was demonstrated following the introduction of serogroup A conjugate vaccination in the African meningitis belt, where vaccination campaigns were followed by substantial reductions in serogroup A disease and evidence of reduced transmission.

The duration of protection remains an important consideration in selecting vaccination strategies. Plain polysaccharide vaccines generally provide relatively short-lived protection, whereas conjugate vaccines can produce more durable immunity. Nevertheless, protection following conjugate vaccination is not necessarily lifelong, as circulating antibody concentrations may wane and effectiveness varies with age and time since immunisation. The implications differ across age groups: infants and young children benefit from the improved immunogenicity of conjugate vaccines. In contrast, adolescents and young adults are important targets in settings where carriage and transmission contribute substantially to disease epidemiology. The balance between direct protection and indirect population-level effects therefore depends on the age groups vaccinated, vaccine coverage, the characteristics of the circulating meningococcal strains and the epidemiological context.

These immunological and epidemiological differences shaped the transition from polysaccharide vaccines used predominantly for outbreak response towards conjugate vaccines suitable for preventive campaigns and routine immunisation. In the African meningitis belt, the introduction of serogroup A conjugate vaccine, MenAfriVac, demonstrated the feasibility of achieving substantial population-level reductions in meningococcal A disease through large-scale preventive vaccination. The subsequent development of multivalent conjugate vaccines reflects the need to extend protection to other epidemic-associated serogroups, including C, W and X. Vaccine selection and implementation must therefore account not only for individual-level efficacy but also for duration of protection, age-specific immunogenicity, serogroup coverage and the potential to reduce transmission.

The WHO sentinel strategy for meningitis control in the 1990s
The “sentinel strategy” was the World Health Organisation’s main policy for combating meningitis epidemics in Africa during the 1990s, a reactive approach born from the constraints of limited vaccine supply and funding. Its logic was epidemiological triage: to use a specific case-rate threshold initially set at 15 cases per 100,000 people per week for two consecutive weeks as a trigger to launch an emergency vaccination campaign in an affected area [26]. This was intended to act as a firebreak, using limited resources to contain an outbreak once it was detected. This was later modified and lowered to 5–10 cases per 100,000 per week for two weeks due to inadequacies noted in the earlier threshold and failure to prevent epidemics [27,28]. However, this strategy was noted to have some weaknesses [29]. The critical weakness was that by the time the threshold was met and confirmed, the epidemic was already in an advanced and explosive phase, making containment nearly impossible. The built-in two-week observation period created a lethal delay, allowing transmission to reach a momentum that a reactive campaign could not halt. This failure was prominently evident in the catastrophic epidemics in Nigeria, Sudan, and Ghana in the mid-1990s, which overwhelmed the sentinel system and demonstrated that waiting for an epidemic to announce itself was a recipe for disaster. The strategy’s inherent slowness and high trigger threshold ultimately proved it was an inadequate defence against the rapid spread of meningococcal meningitis, paving the way for the paradigm shift towards proactive, preventive mass vaccination [29].

The Bauchi mass vaccination campaign, Nigeria (1978–1980): Evidence from a regional experience
The Bauchi meningococcal vaccination campaign of 1978–1980 represents an important early field experience in the use of polysaccharide vaccines for meningococcal disease control in the African meningitis belt [30,31]. Conducted during a period when evidence on the effectiveness and operational feasibility of large-scale vaccination in African epidemic settings was still developing, the campaign provided valuable observational evidence on the potential contribution of bivalent serogroup A and C polysaccharide (PS) vaccines to epidemic control.

The campaign was launched during a major meningitis epidemic in 1978, targeting children aged 3–15 years with the Institut Mérieux bivalent A+C vaccine. Over a three-year period, approximately 2.5 million individuals were immunised across Bauchi State [31]. Reported cases of meningococcal disease declined from 1,585 in 1978 to zero by 1981, and no major epidemic was reported in the state for the following six years. No adverse events were documented among the vaccinated population, underscoring the vaccine’s safety and operational feasibility. Mass vaccination was extended for six additional years across the Northeastern states and Plateau State, reaching a total of 7.5 million individuals [30]. Annual serological assessments of randomly selected vaccine recipients demonstrated high antibody titres against both serogroups A and C, with stronger responses to serogroup A. Antibody persistence was observed for up to five years, though responses were lower in children under one year of age and declined gradually over time. These findings supported the recommendation for revaccination every four years to sustain population immunity [32]. Collectively, the campaign and associated serological assessments provided complementary evidence of immunogenicity and operational feasibility

The Bauchi experience also clarified critical strategic principles. High population coverage was essential to interrupt transmission, whereas selective vaccination approaches were ineffective due to continued importation of cases from unvaccinated communities. This finding strengthened the argument for mass vaccination.  Evidence from the African meningitis belt shows that selective vaccination is a high-risk strategy and is largely ineffective outside of rare, controlled circumstances. While Greenwood and Wali’s 1979 success in a small, pre-mapped Zaria community is notable [33], it is the exception that proves the rule.

This targeted approach fails at scale. As Spiegel et al. demonstrated in Chad, selective vaccination during a severe epidemic was a failure, while mass immunisation of the entire population proved both effective and feasible [34]. Similarly, Chippaux et al. linked Niger’s massive outbreak directly to sustained low vaccine coverage (<25%), which showed a critical lesson that preventive immunisation is both a lifesaver and a cost-saver than reactive vaccination campaigns [35]. These experiences support the importance of coverage, timeliness and implementation capacity.

Experiences outside Africa provided additional evidence of the potential public-health benefits of meningococcal polysaccharide vaccination. In Finland, a mass vaccination campaign conducted in 1975–1976 followed a serogroup A epidemic that had peaked in 1974 [36]. In Mongolia, a campaign involving approximately 65,000 children during the 1974–1975 epidemic was associated with substantially higher meningitis rates among unvaccinated than vaccinated children [37]. In Benin, vaccination campaigns in Atacora and Borgou during 1993–1996 reportedly achieved coverage exceeding 50%, with the reported experience suggesting potential protection against the regional burden of serogroup A disease [38]. These findings, together with evidence from The Gambia [39], contributed to the wider body of evidence supporting the use of polysaccharide vaccines for meningococcal disease control.

Taken together, the Bauchi campaign was an important contribution to the historical evidence supporting large-scale meningococcal vaccination in Africa. Its significance lies in demonstrating the operational feasibility of delivering polysaccharide vaccines at scale and documenting a substantial decline in reported disease following implementation. Considered alongside serological findings and experiences from other settings, it strengthened the rationale for broader vaccination strategies where epidemiological conditions and implementation capacity supported their use.

The challenges of preventive vaccination in meningitis control
Despite encouraging findings from Bauchi and other early vaccination campaigns, the 1980s and early 1990s did not see the emergence of a consistent, internationally coordinated policy for preventive mass vaccination against meningococcal disease in the African meningitis belt. Vaccination strategies varied across settings, reflecting differences in available resources, implementation capacity, epidemiological priorities and uncertainty regarding the benefits and limitations of first-generation polysaccharide (PS) vaccines. Although these vaccines could induce protective antibody responses, their T-cell-independent mechanism limited immunological memory and the duration of protection, particularly in young children. These limitations, alongside the financial and logistical demands of sustained vaccination programmes, complicated decisions about their role in routine immunisation and preventive campaigns.

Nevertheless, the limitations of PS vaccines did not preclude their potential value in specific epidemiological contexts. Evidence from early campaigns suggested that they could contribute to the control of meningococcal epidemics, although the magnitude and duration of population-level protection varied across settings [30-35]. The distinction between their limitations for routine childhood immunisation and their potential utility in epidemic prevention was therefore important in evaluating vaccination policy. Greater consistency in assessing the evidence, alongside consideration of local disease patterns, vaccine coverage, operational feasibility and competing public-health priorities, could have informed more systematic decisions regarding their use.

The consequences of persistent susceptibility in the region became particularly apparent during the 1996 meningococcal epidemic. The World Health Organization reported 152,693 cases and 16,213 deaths globally, while affected regions recorded an additional 60,861 cases and 6,027 deaths [40]. In Nigeria, 109,580 cases and 11,717 deaths were reported [41]. These figures illustrate the substantial public-health burden of meningococcal disease and the challenges of relying heavily on reactive responses during large epidemics. Although incomplete population immunity may have contributed to vulnerability in some settings, the magnitude of the 1996 epidemic also needs to be interpreted in the context of epidemic dynamics, population susceptibility, surveillance and reporting, and the operational constraints affecting prevention and control. The experience reinforced the importance of evaluating preventive vaccination strategies alongside timely outbreak detection, preparedness and effective epidemic response.

MenAfriVac and the lessons of the 1996 epidemic
The 1996 meningococcal epidemic, one of the largest recorded in the African meningitis belt, highlighted the substantial burden of meningococcal disease and the limitations of existing prevention and outbreak-control strategies. Although the epidemic cannot be attributed solely to the absence of a coordinated preventive vaccination policy, it renewed attention to the need for sustained vaccination alongside effective surveillance, preparedness and outbreak response.

The epidemic contributed to renewed international efforts to improve meningococcal disease prevention, including the Meningitis Vaccine Project (MVP) [42]. Through collaboration between the World Health Organization (WHO), PATH and other partners, MVP supported the development of MenAfriVac, an affordable serogroup A meningococcal conjugate vaccine designed for use in the African meningitis belt. Compared with first-generation polysaccharide vaccines, MenAfriVac offered important immunological advantages, including stronger responses in young children and the capacity to induce immunological memory. Its development and deployment also demonstrated the importance of integrating vaccine research, financing, manufacturing, regulatory processes and programme implementation.

The substantial decline in serogroup A meningococcal disease following MenAfriVac introduction represented a major public-health achievement [43,44]. This experience demonstrated the effectiveness of conjugate vaccination when supported by coordinated implementation and high population coverage. It also complemented the earlier Bauchi campaign, which provided evidence of the operational feasibility of large-scale polysaccharide vaccination under field conditions. However, the two experiences differed in vaccine technology, supporting evidence and the extent of programme coordination.

The continued occurrence of meningococcal disease caused by serogroups other than A underscores the need to adapt vaccination strategies to changing epidemiological patterns. The development and introduction of the pentavalent meningococcal conjugate vaccine (Men5CV), which targets serogroups A, C, W, Y and X, represents an important step towards broader protection. These advances align with the WHO Defeating Meningitis by 2030 road map, which aims to eliminate bacterial meningitis epidemics, reduce cases of vaccine-preventable bacterial meningitis by 50% and deaths by 70%, and reduce disability associated with meningitis. Achieving these goals in West Africa will require sustained and equitable vaccination coverage, effective surveillance, strengthened epidemic preparedness and response, and reliable vaccine supply.

Current WHO recommendations for meningococcal vaccination in the African meningitis belt
The World Health Organization (WHO) recommends that countries in the African meningitis belt introduce a single dose of the pentavalent meningococcal conjugate vaccine (Men5CV), targeting serogroups A, C, W, Y and X, into their routine childhood immunisation schedules, typically at 9–18 months of age [45]. WHO also recommends one-off preventive mass vaccination campaigns in high-risk countries and districts to rapidly reduce the burden of meningococcal disease. Countries with high endemic rates (>10 cases per 100,000 population per year), intermediate endemic rates (2–10 cases per 100,000 population per year), and/or frequent epidemics should consider appropriate large-scale meningococcal vaccination programmes. High-quality disease surveillance and systematic evaluation of vaccination programmes remain essential for guiding implementation, monitoring vaccine impact and informing future prevention strategies.

Conclusion

The history of epidemic meningococcal meningitis in West Africa illustrates the importance of aligning scientific advances with timely, coordinated and equitable implementation. The Bauchi campaign provided an important early field experience, while the 1996 epidemic highlighted the limitations of existing prevention and outbreak-response strategies. The subsequent impact of MenAfriVac demonstrated the public-health benefits of conjugate vaccination supported by international collaboration and effective programme implementation.

Men5CV offers an opportunity to extend protection against additional meningococcal serogroups. Progress towards the WHO 2030 targets will require evidence-based vaccination strategies, equitable coverage, strengthened surveillance, effective epidemic preparedness and response, and sustainable vaccine supply. Together, these priorities can help translate advances in vaccine development into sustained public-health benefits.

What is already known about the topic

  • Epidemic meningococcal meningitis has caused recurrent outbreaks in the African meningitis belt for more than a century, resulting in substantial morbidity and mortality across West Africa.
  • First-generation meningococcal polysaccharide vaccines provided protection against targeted serogroups and were useful in epidemic control, but their limitations included weaker immune responses in young children, limited immunological memory and relatively short-lived protection.
  • The introduction of MenAfriVac was followed by a substantial reduction in serogroup A meningococcal disease, demonstrating the public-health benefits of conjugate vaccination and large-scale preventive immunisation.

What this review adds

  • This narrative review brings together historical and epidemiological evidence to contextualise the Bauchi mass vaccination campaign (1978–1980), the 1996 meningococcal epidemic and the introduction of MenAfriVac within the evolution of meningococcal vaccination policy in West Africa.
  • It examines how early field experiences, vaccine characteristics, resource availability, surveillance and programme implementation capacity influenced the transition from predominantly reactive outbreak control towards preventive vaccination strategies.
  • Drawing lessons from these historical experiences, the review identifies priorities for the introduction and implementation of Men5CV, including equitable vaccine coverage, context-appropriate vaccination strategies, strengthened surveillance, sustained epidemic preparedness and reliable regional vaccine supply.

Competing interest

The authors of this work declare no competing interests.

Funding

The authors did not receive any specific funding for this work.

Acknowledgements

This review is dedicated to the people of West Africa affected by meningococcal meningitis and to the healthcare workers and public health personnel involved in preventing and responding to meningitis outbreaks across the region.

Authors’ contributions

Conceptualization: Idris Mohammed
Project Administration: Ibrahim Adamu; Idris Mohammed
Supervision: Idris Mohammed
Writing – Original Draft: Ibrahim Adamu; Umar Yahya Adamu; Dayyibatu Sani Jauro; Idris Mohammed
Writing – Review & Editing: Ibrahim Adamu; Umar Yahya Adamu; Dayyibatu Sani Jauro; Idris Mohammed

 

References

  1. Vieusseux M. [Memory of the illness that reigned in Geneva in the spring of 1805]. J Med Chir Pharmacol [Print]. 1805;11:163-82. French.
  2. Chalmers AJ, O’Farrell WR. Preliminary remarks upon epidemic cerebrospinal meningitis as seen in the Anglo-Egyptian Sudan. J Trop Med Hyg [Print]. 1916;19:101-16.
  3. McGahey K. Report on an outbreak of epidemic cerebro-spinal meningitis in Zungeru during February and March 1905. J Trop Med Hyg [Print]. 1905;8:210-6.
  4. Molesworth AM, Thomson MC, Connor SJ, Cresswell MP, Morse AP, Shears P, Hart CA, Cuevas LE. Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa. Trans R Soc Trop Med Hyg [Internet]. 2002 Jun 1 [cited 2026 Nov 18];96(3):242-9. Available from: https://academic.oup.com/trstmh/article-abstract/96/3/242/1921676 doi:10.1016/s0035-9203(02)90089-1
  5. Hassabu M. Historical background and epidemiology of cerebrospinal meningitis (CSM). Sudan J Paediatr [Internet]. 2013 [cited 2026 Nov 18];13(2):115-23. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4949934/
  6. Greenwood B. Editorial: 100 years of epidemic meningitis in West Africa – has anything changed? Trop Med Int Health [Internet]. 2006 Jun 2 [cited 2026 Nov 18];11(6):773-80. Available from: https://onlinelibrary.wiley.com/doi/10.1111/j.1365-3156.2006.01639.x doi:10.1111/j.1365-3156.2006.01639.x
  7. Lapeyssonnie L. Cerebrospinal meningitis in Africa. Bull World Health Organ [Internet]. 1963 [cited 2026 Nov 18];28(Suppl):1-114. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2554630/
  8. McGahey K. Report of the outbreak of cerebrospinal meningitis at Yola. J Trop Med Hyg [Print]. 1905;8:216-7.
  9. Horn AE. An investigation of cerebrospinal fever in the northern territories of the Gold Coast in 1908. Trans R Soc Trop Med Hyg [Internet]. 1908 Oct [cited 2026 Nov 18];2(1):1-40. doi:10.1016/S0035-9203(08)90002-X
  10. Coulibaly S. Summary of meningitis outbreaks across the world from 1905 to 2016. J Tradit Med Clin Naturop [Internet]. 2017 Aug 30 [cited 2026 Nov 18];6:1-4. Available from: https://www.omicsonline.org/open-access/summary-of-meningitis-outbreaks-across-the-world-from-1905-to-2016.php?aid=92525 doi:10.4172/2573-4555.1000237
  11. World Health Organization. Cerebrospinal meningitis in Africa. Wkly Epidemiol Rec [Internet]. 1996 Oct 11 [cited 2026 Nov 18];71(42):318-9. Available from: https://iris.who.int/server/api/core/bitstreams/0bb11be1-3755-4471-9840-867708aff18a/content
  12. Trotter CL, Lingani C, Fernandez K, Cooper LV, Bita A, Tevi-Benissan C, Ronveaux O, Préziosi MP, Stuart JM. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance data. Lancet Infect Dis [Internet]. 2017 May 22 [cited 2026 Nov 18];17(8):867-72. Available from: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30301-8/fulltext doi:10.1016/s1473-3099(17)30301-8
  13. Djingarey MH, Diomandé FVK, Barry R, Kandolo D, Shirehwa F, Lingani C, Novak RT, Tevi-Benissan C, Perea W, Preziosi MP, LaForce FM. Introduction and rollout of a new group A meningococcal conjugate vaccine (PsA-TT) in African meningitis belt countries, 2010–2014. Clin Infect Dis [Internet]. 2015 Nov 9 [cited 2026 Nov 18];61(Suppl 5):S434-41. Available from: https://academic.oup.com/cid/article/61/suppl_5/S434/418141 doi:10.1093/cid/civ551
  14. Fernandez K, Lingani C, Aderinola OM, Goumbi K, Bicaba B, Edea ZA, Glèlè C, Sarkodie B, Tamekloe A, Ngomba A, Djingarey M, Bwaka A, Perea W, Ronveaux O. Meningococcal meningitis outbreaks in the African meningitis belt after meningococcal serogroup A conjugate vaccine introduction, 2011–2017. J Infect Dis [Internet]. 2019 Oct 31 [cited 2026 Nov 18];220(Suppl 4):S225-32. Available from: https://academic.oup.com/jid/article/220/Supplement_4/S225/5610780 doi:10.1093/infdis/jiz355
  15. Nnadi C, Oladejo J, Yennan S, Ogunleye A, Agbai C, Bakare L, Abdulaziz M, Mohammed A, Stephens M, Sumaili K, Ronveaux O, Maguire H, Karch D, Dalhat M, Antonio M, Bita A, Okudo I, Nguku P, Novak R, Bolu O, Shuaib F, Ihekweazu C. Large outbreak of Neisseria meningitidis serogroup C — Nigeria, December 2016–June 2017. MMWR Morb Mortal Wkly Rep [Internet]. 2017 Dec 15 [cited 2026 Nov 18];66(49):1352-6. Available from: https://www.cdc.gov/mmwr/volumes/66/wr/mm6649a3.htm doi:10.15585/mmwr.mm6649a3
  16. Sidikou F, Zaneidou M, Alkassoum I, Schwartz S, Issaka B, Obama R, Lingani C, Tate A, Ake F, Sakande S, Ousmane S, Zanguina J, Seidou I, Nzeyimana I, Mounkoro D, Abodji O, Wang X, Taha MK, Moulia-Pelat JP, Pana A, Kadade G, Ronveaux O, Novak R, Oukem-Boyer OOM, Meyer S. Emergence of epidemic Neisseria meningitidis serogroup C in Niger, 2015: an analysis of national surveillance data. Lancet Infect Dis [Internet]. 2016 Aug 22 [cited 2026 Nov 18];16(11):1288-94. Available from: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(16)30253-5/abstract doi:10.1016/s1473-3099(16)30253-5
  17. Nathan N, Rose AMC, Legros D, Tiendrebeogo SRM, Bachy C, Bjørløw E, Firmenich P, Guerin PJ, Caugant DA. Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis [Internet]. 2007 Jun [cited 2026 Nov 18];13(6):920-3. Available from: https://wwwnc.cdc.gov/eid/article/13/6/06-0940_article doi:10.3201/eid1306.060940
  18. Vollum RL, Griffiths PWW. An experiment in the prevention of meningococcal meningitis in Nigeria. J Clin Pathol [Internet]. 1962 Jan 1 [cited 2026 Nov 18];15(1):50-3. Available from: https://jcp.bmj.com/content/15/1/50 doi:10.1136/jcp.15.1.50
  19. Alexander CE, Sanborn WR, Cherriere G, Crocker WH, Ewald PE, Kay CR. Sulfadiazine-resistant group A Neisseria meningitidis. Science [Internet]. 1968 Sep 6 [cited 2026 Nov 18];161(3845):1019. Available from: https://www.science.org/doi/10.1126/science.161.3845.1019 doi:10.1126/science.161.3845.1019
  20. de Morais JS, Munford RS, Risi JB, Antezana E, Feldman RA. Epidemic disease due to serogroup C Neisseria meningitidis in Sao Paulo, Brazil. J Infect Dis [Internet]. 1974 May 1 [cited 2026 Nov 18];129(5):568-71. Available from: https://academic.oup.com/jid/article-abstract/129/5/568/886942 doi:10.1093/infdis/129.5.568
  21. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med [Internet]. 1969 Jun 1 [cited 2026 Nov 18];129(6):1307-26. Available from: https://rupress.org/jem/article/129/6/1307/1314/HUMAN-IMMUNITY-TO-THE-MENINGOCOCCUS-I-THE-ROLE-OF doi:10.1084/jem.129.6.1307
  22. Patel M, Lee C. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane Database Syst Rev [Internet]. 2000 Oct 23 [cited 2026 Nov 18]:CD001093. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001093/full doi:10.1002/14651858.CD001093
  23. Cadoz M. Potential and limitations of polysaccharide vaccines in infancy. Vaccine [Internet]. 1998 Aug [cited 2026 Nov 18];16(14-15):1391-5. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0264410X98000978 doi:10.1016/S0264-410X(98)00097-8
  24. World Health Organization. Meningococcal meningitis: emergency preparedness and response [Internet]. Geneva (Switzerland): World Health Organization; [date unknown] [cited 2026 Nov 18]. Available from: http://www.who.int/csr/disease/meningococcal/en/
  25. Flitter BA, Ismail A, Vu D, Granoff DM. Group A antibody persistence five years after meningococcal polysaccharide vaccination in the Sudan. Hum Vaccin [Internet]. 2007 Feb 9 [cited 2026 Nov 18];3(4):135-8. Available from: https://www.tandfonline.com/doi/abs/10.4161/hv.3.4.4308 doi:10.4161/hv.3.4.4308
  26. Moore PS, Plikaytis BD, Bolan GA, Oxtoby MJ, Yada A, Zoubga A, Reingold AL, Broome CV. Detection of meningitis epidemics in Africa: a population-based analysis. Int J Epidemiol [Internet]. 1992 Feb 1 [cited 2026 Nov 18];21(1):155-62. Available from: https://academic.oup.com/ije/article-abstract/21/1/155/655468 doi:10.1093/ije/21.1.155
  27. Varaine F, Caugant DA, Riou JY, Kondé MK, Soga G, Nshimirimana D, Muhirwa G, Ott D, Høiby EA, Fermon F, Moren A. Meningitis outbreaks and vaccination strategy. Trans R Soc Trop Med Hyg [Internet]. 1997 Jan 1 [cited 2026 Nov 18];91(1):3-7. Available from: https://academic.oup.com/trstmh/article-abstract/91/1/3/1924649 doi:10.1016/s0035-9203(97)90371-0
  28. Lewis R, Nathan N, Diarra L, Belanger F, Paquet C. Timely detection of meningococcal meningitis epidemics in Africa. Lancet [Internet]. 2001 Jul 28 [cited 2026 Nov 18];358(9278):287-93. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(01)05484-8/abstract doi:10.1016/s0140-6736(01)05484-8
  29. Robbins JB, Schneerson R, Gotschlich EC, Mohammed I, Nasidi A, Chippaux JP, Bernardino L, Maiga MA. Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines. Bull World Health Organ [Internet]. 2003 Nov 25 [cited 2026 Nov 18];81(10):745-50; discussion 751-5. Available from: https://pubmed.ncbi.nlm.nih.gov/14758435/ doi:10.1590/S0042-96862003001000010
  30. Mohammed I, Obineche EN, Onyemelukwe GC, Zaruba K. Control of epidemic meningococcal meningitis by mass vaccination. I. Further epidemiological evaluation of groups A and C vaccines in northern Nigeria. J Infect [Internet]. 1984 Sep [cited 2026 Nov 18];9(2):190-6. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0163445384914294 doi:10.1016/s0163-4453(84)91429-4
  31. Mohammed I, Zaruba K. Control of epidemic meningococcal meningitis by mass vaccination. Lancet [Internet]. 1981 Jul 11 [cited 2026 Nov 18];318(8237):80-3. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(81)90423-2/fulltext doi:10.1016/S0140-6736(81)90423-2
  32. Mohammed I, Damisah MM. The immunological response to polyvalent meningococcal vaccine in Bauchi State, Nigeria. Trans R Soc Trop Med Hyg [Internet]. 1982 Jan 1 [cited 2026 Nov 18];76(3):351-3. Available from: https://academic.oup.com/trstmh/article-abstract/76/3/351/1868529 doi:10.1016/0035-9203(82)90188-2
  33. Greenwood BM, Wali SS. Control of meningococcal infection in the African meningitis belt by selective vaccination. Lancet [Internet]. 1980 Apr 5 [cited 2026 Nov 18];315(8171):729-32. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(80)91230-1/fulltext doi:10.1016/S0140-6736(80)91230-1
  34. Spiegel A, Greindl Y, Lippeveld T, Decam C, Granga D, Nahor N, Bordonado JL, Sperber G, Yankalbe M, Baudon D. [Effect of 2 vaccination strategies on developments during the epidemic of meningococcal A meningitis in N’Djamena (Chad) in 1988]. Bull World Health Organ [Internet]. 1993 [cited 2026 Nov 18];71(3-4):311-5. French. Available from: https://pubmed.ncbi.nlm.nih.gov/8324849/
  35. Chippaux JP, Campagne G, Djibo S, Cissé L, Hassane A, Kanta I. Preventive immunisation could reduce the risk of meningococcal epidemics in the African meningitis belt. Ann Trop Med Parasitol [Internet]. 1999 Jul 1 [cited 2026 Nov 18];93(5):505-10. Available from: https://www.documentation.ird.fr/hor/fdi:010018757 doi:10.1080/00034989958249
  36. Peltola H. Group A meningococcal polysaccharide vaccine and course of the group A meningococcal epidemic in Finland. Scand J Infect Dis [Internet]. 1978 [cited 2026 Nov 18];10(1):41-4. Available from: https://www.tandfonline.com/doi/abs/10.3109/inf.1978.10.issue-1.09 doi:10.3109/inf.1978.10.issue-1.09
  37. Jamba G, Bytchenko B, Causse G, Cvjetanović B, Očirvan G, Tsend N, Kupul J, Tseren S, Batsuri A, Hisigdorj A, Burian V. Immunization during a cerebrospinal meningitis epidemic in the Mongolian People’s Republic, 1974-75. Bull World Health Organ [Internet]. 1979 [cited 2026 Nov 18];57(6):943-6. Available from: https://pubmed.ncbi.nlm.nih.gov/317021/
  38. Hassan J, Massougbodji A, Chippaux JP, Massit B, Josse R. Meningococcal immunisation and protection from epidemics. Lancet [Internet]. 1998 Aug 1 [cited 2026 Nov 18];352(9125):407-8. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)60508-9/fulltext doi:10.1016/s0140-6736(05)60508-9
  39. Greenwood BM, Smith AW, Hassan-King M, Bijlmer HA, Shenton FC, Hughes ASB, Nunn PP, Jack AD, Cowers PRS. The efficacy of meningococcal polysaccharide vaccine in preventing group A meningococcal disease in The Gambia, West Africa. Trans R Soc Trop Med Hyg [Internet]. 1986 Jan 1 [cited 2026 Nov 18];80(6):1006-7. Available from: https://academic.oup.com/trstmh/article-abstract/80/6/1006/1884720 doi:10.1016/0035-9203(86)90303-2
  40. Salem Press. Meningitis outbreak proves deadly in West Africa [Internet]. [place unknown]: Salem Press; 2020 [cited 2026 Nov 18]. Available from: https://salempress.com/Media/SalemPress/Downloads/Pandemics_Final.pdf
  41. Mohammed I, Nasidi A, Alkali AS, Garbati MA, Ajayi-Obe EK, Audu KA, Usman A, Abdullahi S. A severe epidemic of meningococcal meningitis in Nigeria, 1996. Trans R Soc Trop Med Hyg [Internet]. 2000 May 1 [cited 2026 Nov 18];94(3):265-70. Available from: https://academic.oup.com/trstmh/article-abstract/94/3/265/1917386 doi:10.1016/s0035-9203(00)90316-x
  42. LaForce FM, Konde K, Viviani S, Préziosi MP. The Meningitis Vaccine Project. Vaccine [Internet]. 2007 Sep 3 [cited 2026 Nov 18];25(Suppl 1):A97-100. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0264410X07004744 doi:10.1016/j.vaccine.2007.04.049
  43. Novak RT, Kambou JL, Diomandé FV, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, Lingani C, Martin SW, Hatcher C, Mayer LW, LaForce FM, Avokey F, Djingarey MH, Messonnier NE, Tiendrébéogo SR, Clark TA. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis [Internet]. 2012 Jul 18 [cited 2026 Nov 18];12(10):757-64. Available from: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(12)70168-8/abstract doi:10.1016/S1473-3099(12)70168-8
  44. World Health Organization Regional Office for Africa. Meningitis A nearly eliminated in Africa through vaccination, reaching more than 235 million people [Internet]. Brazzaville (Republic of Congo): WHO AFRO; 2016 Feb 23 [cited 2026 Nov 18]; [about 6 screens]. Available from: https://www.afro.who.int/news/meningitis-nearly-eliminated-africa-through-vaccination-reaching-more-235-million-people
  45. World Health Organization. Meningococcal meningitis [Internet]. Geneva (Switzerland): World Health Organization; c2026 [cited 2026 Nov 18]. Available from: https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/meningitis
Views: 48